Soligenix, Inc. (SNGX)Healthcare | Biotechnology | Princeton, United States | NasdaqCM
1.25 USD
+0.08
(6.838%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.22 -0.03 (-0.033%) ⇩ (April 17, 2026, 7:56 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:04 a.m. EDT
Strong buy recommendation is deceptive; this is a distressed biotech generating persistent operating cash flow deficits, with negative earnings, high beta volatility, and a statistical model forecasting a double-digit decline over the next month following a failed public offering. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.144473 |
| AutoETS | 0.154479 |
| MSTL | 0.168350 |
| AutoARIMA | 0.186015 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.267 |
| Excess Kurtosis | 0.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.767 |
| Market Cap | 12,882,599 |
| Forward P/E | -1.47 |
| Beta | 1.94 |
| Website | https://www.soligenix.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.39613527 |
| Address1 | 29 Emmons Drive |
| Address2 | Suite B-10 |
| All Time High | 3,600,000.0 |
| All Time Low | 1.0 |
| Ask | 1.26 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 179,890 |
| Average Daily Volume3 Month | 229,313 |
| Average Volume | 229,313 |
| Average Volume10Days | 179,890 |
| Beta | 1.938 |
| Bid | 1.22 |
| Bid Size | 2 |
| Book Value | 0.525 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.25 |
| Current Ratio | 2.392 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.25 |
| Day Low | 1.17 |
| Debt To Equity | 6.767 |
| Display Name | Soligenix |
| Dividend Date | 1,475,798,400 |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -11,842,252 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.448 |
| Enterprise Value | 5,304,590 |
| Eps Current Year | -0.85 |
| Eps Forward | -0.85 |
| Eps Trailing Twelve Months | -2.14 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 609 452 6467 |
| Fifty Day Average | 1.1586 |
| Fifty Day Average Change | 0.09140003 |
| Fifty Day Average Change Percent | 0.07888834 |
| Fifty Two Week Change Percent | -39.613525 |
| Fifty Two Week High | 6.23 |
| Fifty Two Week High Change | -4.98 |
| Fifty Two Week High Change Percent | -0.79935795 |
| Fifty Two Week Low | 1.0 |
| Fifty Two Week Low Change | 0.25 |
| Fifty Two Week Low Change Percent | 0.25 |
| Fifty Two Week Range | 1.0 - 6.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 765,466,200,000 |
| Float Shares | 9,760,578 |
| Forward Eps | -0.85 |
| Forward P E | -1.4705882 |
| Free Cashflow | -6,309,460 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00153 |
| Held Percent Institutions | 0.09486 |
| Implied Shares Outstanding | 10,306,079 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.soligenix.com/invest_sec.shtml |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,717,632,000 |
| Last Split Factor | 1:16 |
| Long Business Summary | Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. |
| Long Name | Soligenix, Inc. |
| Market | us_market |
| Market Cap | 12,882,599 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28075 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -11,080,380 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,831,068 |
| Number Of Analyst Opinions | 2 |
| Open | 1.18 |
| Operating Cashflow | -10,266,553 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 609 538 8200 |
| Post Market Change | -0.033499956 |
| Post Market Change Percent | -2.6799965 |
| Post Market Price | 1.2165 |
| Post Market Time | 1,776,470,205 |
| Previous Close | 1.17 |
| Price Eps Current Year | -1.4705882 |
| Price Hint | 4 |
| Price To Book | 2.3809526 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.145 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.08 |
| Regular Market Change Percent | 6.83761 |
| Regular Market Day High | 1.25 |
| Regular Market Day Low | 1.17 |
| Regular Market Day Range | 1.17 - 1.25 |
| Regular Market Open | 1.18 |
| Regular Market Previous Close | 1.17 |
| Regular Market Price | 1.25 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 565,982 |
| Return On Assets | -0.81347 |
| Return On Equity | -2.35497 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 10,306,079 |
| Shares Percent Shares Out | 0.0643 |
| Shares Short | 662,209 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 686,559 |
| Short Name | Soligenix, Inc. |
| Short Percent Of Float | 0.0644 |
| Short Ratio | 2.1 |
| Source Interval | 15 |
| State | NJ |
| Symbol | SNGX |
| Target High Price | 20.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 15.0 |
| Target Median Price | 15.0 |
| Total Cash | 7,936,153 |
| Total Cash Per Share | 0.77 |
| Total Debt | 358,144 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.6486 |
| Two Hundred Day Average Change | -0.39859998 |
| Two Hundred Day Average Change Percent | -0.24178089 |
| Type Disp | Equity |
| Volume | 565,982 |
| Website | https://www.soligenix.com |
| Zip | 8,540 |